AnaMar Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
8
- Latest Deal Type
-
2ndary - Private
AnaMar General Information
Description
Developer of novel therapeutic drugs intended to prevent, heal, and slow organ scarring due to fibrotic disease. The company's drugs target the extracellular matrix producing myofibroblast to treat systemic sclerosis, enabling physicians to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile.
Contact Information
Website
www.anamar.com(Operating Subsidiary)
Corporate Office
- Birger Jarlsgatan 57
- Floor 7
- 113 56 Stockholm
- Sweden
Corporate Office
- Birger Jarlsgatan 57
- Floor 7
- 113 56 Stockholm
- Sweden
AnaMar Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 4. Secondary Transaction - Private | 03-Jun-2013 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC | 07-Nov-2008 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 01-Jan-2002 | Completed | Startup | |||
| 1. Merger/Acquisition | 01-Jan-1998 | Completed | Startup |
AnaMar Patents
AnaMar Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024245894-A1 | (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1h-pyrazole-1-carboximidamide hydrochloride and dermal formulations thereof | Inactive | 26-May-2023 | ||
| WO-2024245895-A1 | Enantioselective preparation method | Inactive | 26-May-2023 | ||
| AU-2020295685-A1 | New tricyclic 5-ht2 antagonists | Inactive | 18-Jun-2019 | ||
| CA-3141747-A1 | New tricyclic 5-ht2 antagonists | Pending | 18-Jun-2019 | ||
| EP-3753924-A1 | New tricyclic 5-ht2 antagonists | Inactive | 18-Jun-2019 | C07D209/60 |
AnaMar Signals
AnaMar Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alestra | Growth/Expansion | Minority | ||
| Allegro Investment Fund | Venture Capital | Minority | ||
| Allenex | Corporation | Minority | ||
| Koncentra | PE-Backed Company | Minority |
AnaMar FAQs
-
When was AnaMar founded?
AnaMar was founded in 1998.
-
Where is AnaMar headquartered?
AnaMar is headquartered in Stockholm, Sweden.
-
What is the size of AnaMar?
AnaMar has 8 total employees.
-
What industry is AnaMar in?
AnaMar’s primary industry is Drug Discovery.
-
Is AnaMar a private or public company?
AnaMar is a Private company.
-
What is AnaMar’s current revenue?
The current revenue for AnaMar is .
-
How much funding has AnaMar raised over time?
AnaMar has raised $9.9M.
-
Who are AnaMar’s investors?
Alestra, Allegro Investment Fund, Allenex, and Koncentra have invested in AnaMar.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process